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Abstract:  Lithium therapy is the gold standard of treatment for patients 
with Bipolar Disorder. However, despite its effectiveness, it is a potentially 
hazardous drug requiring regular monitoring of blood levels to ensure toxic 
levels are not reached. This paper describes the spectrophotometric analysis 
of Lithium carbonate in solution as a first step in developing a portable 
home monitoring device for blood lithium analysis.. Using a high-end 
spectrophotometer, solutions of lithium carbonate (Li2CO3) have been 
optically fingerprinted. Preliminary measurements indicate that the 
ultraviolet region shows a strong distinction between different lithium 
concentrations. Utilizing second derivative absorption curves, the region of 
220 nm to 230 nm demonstrated the ability to differentiate between 
concentrations representing those found in patients. Furthermore, the 
method could determine to within a 1–6% accuracy whether an unknown 
solution of Li2CO3 is either inside or outside the high-end of the therapeutic 
limit.  
tissue diagnostics. 
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1. Introduction  
Bipolar disorder is a chronic condition, characterized by recurring episodes of depressed and 
manic mood states [1]. In its more severe forms, bipolar disorder is associated with significant 
impairment of personal and social functioning, and with high risk of death through suicide as 
well as poor physical health. It is estimated to affect up to 254 million worldwide [2], often 
developing between the ages of 18 and 24 years.  
Lithium, prescribed in the form of a carbonate (Li2CO3) or citrate (Li3C6H5O7), is a widely 
used medication for treating bipolar disorder [3], reducing the frequency and intensity of 
mood swings and suicidal tendencies. However, despite its effectiveness, it is a potentially 
hazardous drug requiring regular monitoring of blood levels to ensure toxic levels are not 
reached. 
Lithium has a very narrow therapeutic index (concentrations ranging from 0.4 to 1.0 mM) 
with the upper limit being uncomfortably close to toxic levels [4]. Toxic lithium levels can 
cause circulatory collapse, kidney failure, neurological abnormalities, seizures, coma and even 
death [4- 6]. For patients newly prescribed lithium medication, the dosage adjustment can take 
months before stability is reached and lithium is within the therapeutic range. Even when 
lithium concentrations are reasonably stable, they can rapidly reach toxic levels during 
intercurrent illness such as febrile conditions and dehydration or the addition of some drugs 
[7]. Therefore, lithium requires regular on-going monitoring to maintain therapeutic levels and 
avoid toxicity [8].  
Determination of blood lithium levels involves relatively complex laboratory methods, such 
as flame photometry or ion-selective electrode analysis, which require withdrawal of blood 
samples and transport of samples to a laboratory [9]. The National Institute for Health and 
Clinical Excellence (NICE) guidelines recommend that lithium levels should be checked one 
week after starting and one week after every dose change until the levels are stable [10]. 
Following stability, NICE recommends that lithium levels are checked every three months. 
However, in a national-level audit of lithium monitoring practice in the UK, it was found that 
contemporary lithium monitoring falls short of the standards recommended by NICE [11]. 
This failure to ensure the safe use of lithium and/or to ensure adequate monitoring of 
established treatment may place patients at risk of avoidable drug related morbidity. 
Furthermore, bipolar patient adherence to lithium therapy is often “erratic” [12]. Reasons 
include frequent blood tests, which can contribute to patients defaulting from treatment. This 
is associated with unacceptably high levels of relapse.  
Currently, there aren’t any non-invasive blood lithium monitors available to enable bipolar 
patients to check their lithium levels at home. Such a device, would put more control into the 
hands of the patient while also providing an early warning that lithium concentrations are 
drifting outside the therapeutic range.  
This research explores the feasibility of optically detecting lithium concentrations, with the 
ultimate goal of providing a portable non-invasive sensing technology for bipolar disorder 
patients. This paper outlines the first steps in optically fingerprinting lithium carbonate in 
order to determine the optical window of interest and the capability of optical techniques to 
identify the concentrations of lithium found in blood.  
  
2. Materials and Methods 
 
Lithium concentrations are typically measured in plasma. However, as a precursor to 
measurements in plasma or whole blood, the optical absorption characteristics of lithium 
carbonate in solution were investigated in order to identify the appropriate wavelengths and 
optical window on which to focus measurements. Furthermore, this investigation would allow 
for the feasibility of optical detection of lithium to be explored. Therefore, solutions of lithium 
carbonate in distilled water were analyzed in the laboratory, including solutions whose 
concentrations reflect those typically found in blood. 
 
2.1 Sample Preparation 
 
Solutions of lithium carbonate (Li2CO3) were prepared in pure distilled water by diluting a 
concentrated solution.  The concentrated solution was prepared using a solid pure (99.999%) 
form of Li2CO3 from Acros Organics (NJ, USA).  As there are two Lithium ions (Li+) in one 
molecule of Li2CO3, it was only necessary to prepare the whole solution to half the desired 
concentration in order to achieve the therapeutic doses of lithium.  Li2CO3 has negative water 
solubility, i.e. the amount able to dissolve into water decreases with increasing temperature. 
Therefore, all samples were prepared and tested at ambient temperature (21°C) to ensure that 
no solute precipitated out of the solution during measurements.  
 
In order to initially identify a spectral region of interest and fingerprint Li2CO3 in solution, a 
batch of solutions with high concentrations was prepared. These solutions are referred to as 
the “Fingerprinting concentrations” (see Table 1). Following this, solutions whose 
concentrations reflect those commonly found in blood were prepared and evaluated to 
determine the ability of optical absorption spectrophotometry to identify Li concentrations 
around the therapeutic window. These solutions are referred to as “Therapeutic 
concentrations” (see Table 1). 
 
Table 1. Concentrations of Li2CO3 in solution of distilled water with the effective Li+ concentration 
Finger Printing Concentrations Therapeutic Concentrations 
Li2CO2 mmol/L Li+ mmol/L Li2CO2 mmol/L Li+ mmol/L 
5.3 10.6 0.1 0.2 
10.7 21.4 0.2 0.4 
21.3 42.6 0.3 0.6 
42.5 85.0 0.4 0.8 
- - 0.5 1.0 
- - 0.6 1.2 
 
2.3 Spectrophotometry Apparatus and Methods 
 
To obtain full spectra of the different fingering printing solutions, a Lambda 1050 dual beam 
UV/Visible/NIR spectrophotometer (Perkin Elmer Inc, Massachusetts, USA) was used with a 
spectral region of 200–3300 nm, thus covering parts of the ultraviolet region, the entire visible 
and NIR, as well as parts of the mid-infrared region. The increment step was set to 1 nm. For 
wavelengths between 200–319.20 nm, the source was a deuterium lamp, while a halogen 
tungsten lamp was used for the range 319.20nm to 3300nm. The detector system was set to 
use a photomultiplier tube detector (PMT) for the shortest wavelengths from 200 nm to 
860.80 nm, an indium gallium arsenide detector (InGaAs) for wavelengths between 860.80–
1800.80 nm and a lead sulphide detector (PbS) for the rest of the spectral region up to 3300 
nm. Slit settings for the PMT detector were fixed at 2 nm, whilst both the InGaAs and PbS 
detectors were set on ‘servo mode’, whereby the system monitors the reference beam energy 
and adjusts the slits accordingly to avoid over saturation of the detectors. Gain settings for the 
detectors were set to 5 for the InGaAs and PbS detectors, while the PMT gain was set on auto 
to allow the instrument to determine the appropriate value. The response time for all detectors 
was set at 0.4 seconds. The front and rear attenuators were set at 100% for both the sample 
and reference beams. Prior to placing the samples in the spectrophotometer, baseline 
corrections (100 %T/0A and 0%T/blocked beam) were performed to remove ‘background 
noise’ and help negate the effects of any stray light in the system.  
First a sample of distilled water was evaluated in the spectrophotometer in order to provide a 
reference, followed by the finger printing concentration samples from Table 1. Each sample 
was contained in a rectangular quartz SUPRASIL cell, made of high purity synthetic fused 
silica material with a light path length of 1 mm (Perkin Elmer Inc, Massachusetts, USA). 
Samples were then placed into the sample compartment whilst a blank optically matched cell 
was inserted into the reference compartment. 
 
Once a spectral region of interest was identified, the scan settings were changed to fix the 
range between 200-315nm (the region where it was observed to be changing with increasing 
Li2CO3 concentrations).  A second derivative of the spectrum in this region was then 
calculated to better identify specific absorption bands. 
 
2.4 Data Analysis 
 
For each sample, spectral measurements were repeated three times, and the results averaged 
and smoothed using a Savitzky-Golay filter in UV WinLab Data Processor and Viewer 
software (Perkin Elmer Inc, Massachusetts, USA).  The second derivative of the curves was 
calculated and spectral bands of interest were identified.  Utilizing UV WinLab’s maths 
functions the peak, maximum height and area under each curve in the bands of interest was 
calculated and saved to a spreadsheet for further analysis. 
 
Using these results, calibration functions were developed in MATLAB® (The MathWorks, 
USA). This was done by fitting the results obtained from UV WinLab to linear and cubic 
functions for all three scans in each therapeutic concentration, and for pure water, which was 
given a lithium concentration value of 0.0 mmol/L for referencing purposes and zero point 
calibration.  Each function was given an R2 correlation score (a value greater than 0.95 for the 
linear fit was established as the correlation limit at which a function was rejected) to help 
determine which function worked best in the [Li+] range of interest. Lastly the “Therapeutic 
concentrations” samples were re-run in the spectrophotometer and their concentrations 
calculated using the cubic calibration functions with R2 > 0.97. 
3. Results 
The resulting absorption spectra of distilled water and the Fingerprinting Li2CO3 solutions are 
shown in Figure 1, after undergoing smoothing to reduce the level of noise. It was easily 
observed that the primary water absorption bands in the infrared regions dominate; however 
the UV band of approximately 200 – 240 nm demonstrated a characteristic slope, increasing 
as the concentrations got higher.  
 
Fig. 1. Full pure water spectrum with various fingerprinting concentrations of Li2CO3 
 
In the UV region of interest the 2nd derivative of batch 1 revealed two distinct absorption 
bands, a narrow bandwidth of approximately 205 – 209 nm (γ207) and a second broader band 
with a bandwidth of approximately 220 - 230 nm (γ225), shown in figure 2 
 
  
Fig. 2. Second derivative absorption curves (200 – 
260 nm), fingerprinting concentrations. 
Fig. 3. Second derivative absorption curves (200 – 
260 nm), therapeutic concentrations. 
The second derivative of the absorption curves for the therapeutic concentrations were 
observed to have less of a distinct peak in the γ225 band, but the general trend of the 
absorbance at the peak value was still observed to increase with increasing concentrations, see 
figure 3.  The calculated R2 value for the linear (L) and cubic (C) fits are summarised in the 
table below, table 2. 
 
Table 2. R2 values for the linear (L) and cubic (C) therapeutic concentration curves for each of the identified 
bands (γ207
 
and γ225) using the peak, maximum height and area under the curve methods. 
 
Peak Max Height Area 
Band L C L C L C 
γ207 0.706 0.898 0.706 0.897 0.706 0.897 
γ225 0.956 0.975 0.906 0.921 0.958 0.976 
 
The best linear fit of concentration verses either peak value, maximum value or area under the 
curve was found to be in the γ225 band (R2 > 0.95).  The cubic fit equations from the area and 
peak values (1 and 2 respectively) were then selected as the calibration functions to be used. 
 
 
BY AREA   266.0107.02051.03071.032  zzzCOLi  
where     00012.0/00019.0 xz
 
(1) 
 
BY PEAK   266.011.02048.03069.032  zzzCOLi  
where     000014.0/00002.0 xz
 
(2) 
and where x is the area under the curve of the second derivative or the peak value of the 
spectrum at each concentration of Li2CO3 in the γ225 band of the therapeutic concentration 
absorption curves.  
The therapeutic concentration samples were re-run, and concentration calculation results are 
shown in table 3. The ability of the spectroscopic method in conjunction with the calibration 
curve to determine the lithium carbonate concentration of solutions decreases with decreasing 
concentration. However, it can sufficiently identify the range of concentration. 
 
Table 3: Li2CO3 concentration calculation from derived calibration functions using the γ225 band. 
Specified 
[Li2CO3]  
(mM) 
Area under 
2nd Derivative 
Calculated 
[Li2CO3] 
(mM) 
(eqn 1) 
% Difference Peak value of 2nd Derivative 
Calculated 
[Li2CO3] 
(mM) 
(eqn 2) 
% Difference 
0.1 0.00004 0.08 23 0.000005 0.11 11 
0.2 0.00015 0.23 15 0.000016 0.24 18 
0.3 0.00018 0.25 15 0.000019 0.26 14 
0.4 0.00029 0.44 11 0.000032 0.49 9 
0.5 0.0003 0.47 6 0.000033 0.46 8 
0.6 0.00033 0.59 1 0.000036 0.57 5 
4. Discussion and Conclusion 
It has been determined that the addition of Li2CO3 to pure water, in concentrations below the 
saturation limit at 25°C, does have a measureable contribution in the deep-UV absorption 
spectra. By observing the second derivative spectra of the Fingerprinting Concentrations, two 
distinct bands were identified: band γ207 (205-209nm) and band γ225 (220 - 230 nm). These 
bands were also identifiable in solutions whose concentrations reflect those typically found in 
blood.  
Using measurements of the peak, maximum height and area under each curve from the second 
derivatives of the bands of interest, linear and cubic fits were applied. From this it was 
determined that in the therapeutic range the γ225-band more accurately represents Li2CO3 
concentrations, as the two calibration functions constructed had a very high correlation 
coefficient (R2 > 0.97). Using these calibration functions to calculate the concentrations on a 
re-run of therapeutic concentrations it was revealed that the higher concentrations could be 
calculated more reliably, with higher accuracy.  It has to be taken into account that a [Li2CO3] 
of 0.5 mM is equal to a therapeutic dose of 1.0 mM, due to the double-lithium ion in the 
Li2CO3 molecule.   
Whilst lithium carbonate in saturation concentrations above about 160 mM at 25 degrees C 
(approximately 1.2g per 100g of water)  is known as a wavelength blocking agent when 
measuring stray light we are working at concentrations far below this (0.1 - 0.6 mM, anything 
above these minute levels is highly toxic), and the effect on the absorption curve we believe is 
quantifiable with the provided calibration function and proven with a good level of accuracy 
in our re-run of the sample, especially at higher therapeutic concentrations where blood 
toxicity starts to become an issue. 
It is therefore reasonable to conclude that with the method of measuring Li2CO3 reported here 
it can be determined to within a 1 – 6% accuracy whether an unknown solution of Li2CO3 is 
either inside or outside the high-end of the therapeutic limit.  
Further investigations are planned to make an attempt at measuring other common medicinal 
lithium compounds in solution to help identify any characteristic in the absorption spectra that 
is solely unique to the lithium ions.  Different mixtures with other common salts that appear in 
blood and other bodily fluids, such as saliva or urine, will also be conducted to investigate the 
effect that these have on the observed absorption curves. 
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